Navigation Links
Ossur® AFO Dynamic

ProductsOssur® AFO Dynamic
Company Ossur
Item Ossur® AFO Dynamic
Features Pre-impregnated carbon fiber:
  • Dynamic motion
  • Energy return
  • High durability
  • Excellent weight to strength ratio
  • Lightweight
    • Footplate design:
  • Stiffness gradient at heel and toe part corresponds to ground reaction forces as they are applied to the foot
    • Gait assistance:
  • Gradual plantar flexion at initial contact
  • Medio-lateral stability at mid-stance
  • Energy return and assisted propulsion of the limb at toe off
  • Supports the foot for ground-clearance during swing phase
    • Profile:
  • Medial strut makes it less visible
  • Simple strap mechanism
  • Open structure on anterior tibia shell
    • Textile:
  • Textile cover on outside of AFO and inside of footplate provides a pleasant cosmetic appearance and keeps fiber residues from coming into contact with the skin
    • Description The Ossur range of prefabricated foot and ankle products resolves a wide variety biomechanical problems - from ankle instability to foot malalignment. Ossur products uniquely combine clinical efficacy, low-profile designs and energy-return technology.

    Age is not important. Its energy that counts. Traditional ankle foot orthoses provide a measure of support, but people leading busy lives need something more. Ossur has taken the best of its Flex-Foot technology and incorporated carbon fiber into the new AFO Dynamic. For real energy return and a confident, more efficient walk, look no further.

    Ossur AFO Dynamic provides a strong, lightweight solution for patients with drop foot secondary to a variety of neurological conditions. The energy storing properties of carbon fiber make it ideal material for this dynamic ankle foot orthosis.

    The AFO Dynamic is now available in a new size - extra small

    Indications:
  • Drop Foot secondary to:
  • CVA (Cerebral Vascular Accident or Stroke)
  • MS (Multiple Sclerosis)
  • Charcot-Marie-Tooth disease
  • Other neurological conditions
    • Info Ossur
    Customer Service: (800) 233-6263
    Web site: http://www.ossur.com

    Related medicine products :

    1. SB Charit Intervertebral Dynamic Disc Spacer
    2. PASCAL Dynamic Contour Tonometer
    3. Xtrem Dynamic electrophysiology catheter
    4. DJD II Dynamic Elbow Joint Distractor
    5. OSStaple™ Dynamic Compression Staple
    6. Procyon P2000SA Dynamic Binocular Pupillometer
    7. The PASCAL Dynamic Contour Tonometer
    8. Comfy™ Dynamic Elbow Torque Orthosis
    9. BODI™ Dynamic Orthosis
    10. Controlled Dynamic Stretch Knee Brace
    11. syngoDynamics
    ...ls cover the range from 2ul to 5000ul. Fills and ...revents inadvertent volume change. Novel hand gri...e is autoclavable at 121C(250F). To prevent corro...le for one-handed operation. Auto or Normal trigg...
    Pipetman Ultra is a fully adjustable, air-displacement pipette with a patented multifunctional electronic display. It is the latest member of the Pipetman family, sharing many of the same characteris
    ...ion, ergonomics, and value!, Comfortable feel and...andle , Finer control while pipetting with smooth,...able for easy decontamination and sterilization wi...ecision micrometer for reproducible, accurate volu...
    ...ls cover the range from 2ul to 5000ul. Fills and ...revents inadvertent volume change. Novel hand gri...e is autoclavable at 121C(250F). To prevent corro...le for one-handed operation. Auto or Normal trigg...
    Medicine Products:
    (Date:8/7/2008)...r continues support of activities fostering total ...erves, PASADENA, Calif., Aug. 7 /PRNewswire/ -- K...based nonprofit organization, today announced that...r of the 2008 Pasadena,Marathon. The inaugural rac...e flagship event for Pasadena Forward., Kaiser Pe...
    (Date:8/7/2008)...recognize best practices in consumer decision-maki...th care management spectrum, WASHINGTON, Aug. 7 /...,than thirty of the nation,s foremost thought lead...or its 2009 Best Practices in Health Care,Consumer...ices awards,recognize innovative and proven progra...
    (Date:8/7/2008)...Aug. 7 /PRNewswire-USNewswire/ -- The U.S. Governm...elopment (USAID), is providing,an initial $50,000 ...rgency,relief supplies to the flood-affected popul...s led to flooding in central and,southeastern Togo...capital,of Lome. The UN Development Program estima...
    (Date:8/7/2008)...rves Beneficiary Access to High Quality Nursing Ho... Staffing Efforts, JOPLIN, Mo., Aug. 7 /PRNewswir... protecting the nation,s critical frontline-caregi...r Care (CPSC) today thanked,Senator Pat Roberts fo...in,Congress to stop the Bush Administration from m...
    Breaking Medicine News(10 mins):Health News:Kaiser Permanente Becomes Presenting Sponsor for Pasadena Marathon 2Health News:URAC Reveals Distinguished Judges' Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards 2Health News:URAC Reveals Distinguished Judges' Panel for 2009 Best Practices in Health Care Consumer Empowerment and Protection Awards 3Health News:Senator Pat Roberts Praised for Leading Successful Effort to Derail $6.2 Million Kansas Medicare Cuts 2
    ...ntries should put their heads together, and share ...cting people across nationalities from a dreaded f...e international effort in the development of a vac...ng of important information regarding influenza vi...
    ...ording to the scientists from the University of Ne...lammatory bowel disease can eliminate the damage c...e usual belief that fibrosis; the scarring linked ...the recent study on animals revealed that the dama...
    ...tland: Many thousands of stroke victims suffer vis...ists in Aberdeen have conceived //a device that ho... impairment of vision. According to the Aberdeen ...been devised that is capable of arousing the blind...
    ... Cape Times has reported that illegal medicines ar...red products being sold on the streets//. The repo...culosis and HIV/Aids.A source in the country's hea...t of control. "The belief is that they can't close...
    Other Medicine News:
    (Date:8/7/2008)...wswire/ -- ProteoTech Inc. (ProteoTech),today anno...onal New Drug,(IND) requirements and has been clea...cal trial on Exebryl-1(R), a novel small molecule ...tion for the treatment of Alzheimer,s,disease. Pro...29, 2008., At the 2008 International Conference o...
    (Date:8/7/2008)...ve Decision to Expand its Proprietary ...rland, Aug. 7 /- ESBATech AG, a leadi...day announced that the,company has raised an addit...ries B venture round to expand its development pip...ticipated in this round including SV Life,Sciences...
    (Date:8/6/2008)...ew Patent Granted, CAMBRIDGE, Mass. and CARLSBAD,...Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, I...e begun a phase 3 study of mipomersen in,patients ...eFH), a genetic,disorder that causes exceptionally...f four new trials the companies plan to initiate b...
    (Date:8/6/2008)...ire/ -- In the most recent issue of,Optometry & Vi...erman,scientist and researcher, Dr. Burkhart Fisch...ion problems have a hard time learning basic,mathe...therapy is given,math skills improve., Dr. Fisch...vision news,programs which reported on his researc...
    Breaking Medicine Technology:ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 2ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing 3Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 2Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 3Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 4Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 5Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 6Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 7Vision Problems Affect How Children Learn Math Skills 2Cato Research Names John Cline as President 3887 1Cato Research Names John Cline as President 3887 2More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 1More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 2More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 14105 3Amilpar Revenues Increase by 32 25 and EBITDA Doubles in 2007 14102 1Amilpar Revenues Increase by 32 25 and EBITDA Doubles in 2007 14102 2Remarks Prepared for Delivery By Attorney General Michael B Mukasey At the Ministerial Press Conference 2474 1Remarks Prepared for Delivery By Attorney General Michael B Mukasey At the Ministerial Press Conference 2474 2
    ...SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ ... wholly-owned,subsidiary of Neurochem Inc. , annou...M) published the results of the "Eprodisate,For AA...ark,clinical trial in the search for a treatment o...clinical trial for eprodisate,(KIACTA(TM)) demonst...
    ...) is evaluating zonisamide SR as a novel component..., June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen...any focused on the,treatment of central nervous sy...oday announced results from a Phase I trial evalua...prietary,sustained-release (SR) formulation of zo...
    Other Medicine Technology:Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4